申请人:Rhone Poulenc Rorer S.A.
公开号:US05990108A1
公开(公告)日:1999-11-23
Compounds of formula (I), wherein R is a hydrogen atom or a --COOH, -alk-COOH, --PO.sub.3 H.sub.2, --CH.sub.2 --PO.sub.3 H.sub.2, or --CH.dbd.CH--COOH radical, or a phenyl radical substituted by a carboxy radical, R.sub.1 is an alk-CN, -alk-COOH, -alk-Het, alk-PO.sub.3 H.sub.2 or -alk-CO--NH--SO.sub.2 R.sub.2 radical, R.sub.2 is an alkyl or phenyl radical, alk is an alkyl radical, Het is a saturated or unsaturated mono- or polycyclic heterocyclic ring containing 1-9 carbon atoms and one or more heteroatoms selected from O, S and N, said heterocyclic ring optionally being substituted by one or more alkyl, phenyl or phenylalkyl radicals, with the proviso that when R is a hydrogen atom or a --COOH or --PO.sub.3 H.sub.2 radical, R.sub.1 cannot be -alk-COOH, isomers, racemic mixtures, enantiomers and diastereoisomers thereof, salts thereof, the preparation thereof, intermediates thereof and drugs containing said compounds, are disclosed. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive antagonists of the N-methyl-D-aspartate (NMDA) receptor, and specifically ligands for NMDA receptor glycine modulator sites. ##STR1##
化合物的化学式(I),其中R是氢原子或--COOH,-烷基-COOH,--PO.sub.3 H.sub.2,--CH.sub.2 --PO.sub.3 H.sub.2或--CH.dbd.CH--COOH基团,或被羧基取代的苯基基团,R.sub.1是烷基-CN,-烷基-COOH,-烷基-Het,烷基-PO.sub.3 H.sub.2或-烷基-CO--NH--SO.sub.2 R.sub.2基团,R.sub.2是烷基或苯基基团,烷基是烷基基团,Het是含有1-9个碳原子和一个或多个异原子(O、S和N)的饱和或不饱和单环或多环杂环环,该杂环环可以选择性地被一个或多个烷基,苯基或苯基烷基基团取代,但是当R是氢原子或--COOH或--PO.sub.3 H.sub.2基团时,R.sub.1不能是-烷基-COOH,其同分异构体,消旋混合物,对映异构体和非对映异构体,以及其盐,其制备方法,其中间体和含有该化合物的药物已被披露。化合物的化学式(I)具有有价值的药理学性质,并且是α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体的拮抗剂,也被称为quisqualate受体。此外,化合物的化学式(I)是N-甲基-D-天冬氨酸(NMDA)受体的非竞争性拮抗剂,特别是NMDA受体甘氨酸调节剂位点的配体。